Can a pill prevent dangerous platelet drops during breast cancer treatment?
NCT ID NCT07198672
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether herombopag tablets can prevent low platelet counts in 45 women with HER2-positive breast cancer who are receiving T-DM1 therapy. T-DM1 is effective but often causes low platelets, especially in Asian patients, which can force treatment delays or dose reductions. Participants will take herombopag at the start of each T-DM1 cycle to see if it keeps platelet levels safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
herombopag olamine tablets
What this could lead to
If it works, this could offer a way to prevent dangerous low platelet counts in HER2+ breast cancer patients on T-DM1, helping them complete their cancer therapy without delays or dose cuts.
What could go wrong
This is a small, early exploratory study with no control group, so results may not be definitive. The drug may not prevent low platelets effectively or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••